FOLD - Amicus Therapeutics reports mixed Q3 earnings; updates FY22 guidance
- Amicus Therapeutics press release ( NASDAQ: FOLD ): Q3 GAAP EPS of -$0.12 beats by $0.08 .
- Revenue of $81.7M (+2.7% Y/Y) misses by $2.5M .
- On-track to deliver Full-Year 2022 double-digit revenue growth of 15-20% at CER vs. consensus of 11% Y/Y growth.
-
Updating Full-Year 2022 non-GAAP operating expense guidance from $470M-$485M to $430M-$440M .
For further details see:
Amicus Therapeutics reports mixed Q3 earnings; updates FY22 guidance